Compare TREX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREX | BLTE |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.0B |
| IPO Year | 1998 | 2021 |
| Metric | TREX | BLTE |
|---|---|---|
| Price | $50.00 | $129.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 9 |
| Target Price | $63.05 | ★ $233.00 |
| AVG Volume (30 Days) | ★ 2.2M | 142.0K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,174,267,000.00 | N/A |
| Revenue This Year | $10.59 | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $29.76 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $30.60 | $115.41 |
| 52 Week High | $60.21 | $200.00 |
| Indicator | TREX | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 32.18 |
| Support Level | $41.15 | N/A |
| Resistance Level | $50.04 | $158.76 |
| Average True Range (ATR) | 2.61 | 9.11 |
| MACD | -0.73 | -1.46 |
| Stochastic Oscillator | 2.85 | 19.04 |
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.